Gazyva® (obinutuzumab)
for Leukemia

Gazyva (obinutuzumab) is an intravenous immunotherapy that treats specific blood cancers by enhancing the immune response. It's approved for adults with chronic lymphocytic leukemia (CLL) as an initial treatment alongside chlorambucil, and follicular lymphoma (FL), either after relapse or inadequate response to rituximab-based treatments, or as a first-time therapy combined with chemotherapy, followed by maintenance treatment if successful.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Leukemia